YieldMax MRNA Option Income Strategy ETF (NYSEARCA:MRNY) Sees Large Growth in Short Interest

YieldMax MRNA Option Income Strategy ETF (NYSEARCA:MRNY – Get Free Report) saw a large growth in short interest in the month of September. As of September 15th, there was short interest totaling 80,671 shares, a growth of 57.3% from the August 31st total of 51,284 shares. Currently, 1.5% of the shares of the stock are short sold. Based on an average daily trading volume, of 218,763 shares, the short-interest ratio is presently 0.4 days.

YieldMax MRNA Option Income Strategy ETF Trading Down 3.8%

MRNY stock traded down $1.60 during trading on Wednesday, reaching $40.21. The company’s stock had a trading volume of 512,731 shares, compared to its average volume of 243,641. The company’s fifty day moving average is $27.20 and its 200-day moving average is $20.93. YieldMax MRNA Option Income Strategy ETF has a 1 year low of $13.60 and a 1 year high of $42.63.

Get YieldMax MRNA Option Income Strategy ETF alerts:

About YieldMax MRNA Option Income Strategy ETF

(Get Free Report)

The YieldMax MRNA Option Income Strategy ETF (MRNY) is an exchange-traded fund that mostly invests in health care equity. The fund seeks to provide current income and capped gains on the Moderna stock (MRNA) through a synthetic covered call strategy, collateralized by cash and US Treasurys. The actively managed fund uses both standardized exchange-traded and FLEX options. MRNY was launched on Oct 23, 2023 and is issued by YieldMax.

See Also

• Five stocks we like better than YieldMax MRNA Option Income Strategy ETF
• Deutsche Bank Makes a Contrarian Call on Netflix—What Does It Mean for Investors?
• O’Reilly Automotive’s Stock Slump Hides a Stronger Business
• McDonald’s Stock Slump Makes Its AI Pricing Bet Even Riskier
• Broadcom’s AI Growth Story Faces a $161 Billion Anthropic Test

Receive News & Ratings for YieldMax MRNA Option Income Strategy ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for YieldMax MRNA Option Income Strategy ETF and related companies with MarketBeat.com's FREE daily email newsletter.